source
- Lilly to buy startup Ajax in bid for a better JAK drugWorth up to $2.3 billion overall, the deal hands Lilly a drug designed to address the weaknesses of a class of medicines used to treat myelofibrosis and other diseases.BioPharma Dive · 3mo ago↗ source
- STAT+: Astellas retries XLMTM gene therapy after deathsVeradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech newsSTAT · 3mo ago↗ source
- STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and moreIntellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with hereditary angioedemaSTAT · 3mo ago↗ source